Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Yiping Wen 1,* , Jing Cai 1,* , Yaya Hou 1 , Zaiju Huang 1 and Zehua Wang 1 1 Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China * These authors have contributed equally to this work Correspondence to: Zehua Wang, email: // Keywords : EZH2, cancer stem cells, sphere, histone lysine methylation, polycomb repressive complex Received : November 02, 2016 Accepted : March 02, 2017 Published : March 22, 2017 Abstract Epigenetic modifications in cancer stem cells largely result in phenotypic and functional heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressor complex 2, is highly expressed in cancer stem cells of numerous malignant tumors and has a critical function in cancer stem cell expansion and maintenance. Here, we review up-to-date information regarding EZH2 expression patterns, functions, and molecular mechanisms in cancer stem cells in various malignant tumors and discuss the therapeutic potential of targeting EZH2 in tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“Other functional domains, such as CXC and ncRBD, are required for interaction with other PRC2 components and regulatory proteins (Figure 1B) [22-24].”
BackgroundThe Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 3×
“As the most potent inhibitor of EZH2, GSK126 shows greater than 1,000-fold selectivity for EZH2 compared with other methyltransferases containing SET or non-SET domains and 150-fold selectivity compared to EZH1 [116, 117].”
BackgroundKim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471 · cited 2×
“Compared to normal tissue cells or benign tumor cells, EZH2 is overexpressed in and promotes tumor progression in various cancers [36].”
BackgroundMerlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934 · cited 1×
“CRC stem-like cells (CCS-like cells) have recently attracted increasing attention due to their contribution to the poor prognosis of cancer patients [71, 72].”
BackgroundA selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776 · cited 2×
“EPZ005687 SAM-competitive inhibitor of PRC2 Yes Preclinical [112]”
Backgroundp53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767 · cited 1×
“c-Myc, which is critical for maintaining self-renewal and survival in glioma CSCs [94, 95], is also regarded as a key molecule involved in genetic reprogramming [96].”
BackgroundRoles of unphosphorylated STATs in signaling
Yang, J., & Stark, G. R. (2008) · Cell Research · doi:10.1038/cr.2008.41 · Cited by 347 · cited 1×
“Activation of STAT3 involves a series of events [79], and recent research identified that STAT3 downstream genes are overexpressed in the mesenchymal GBM subtype, supporting that STAT3 signaling has a key function in controlling mesenchymal transformation in glioma [80, 81].”
Background
Cited by
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
FOXM1 drives proximal tubule proliferation during repair from acute ischemic kidney injury
Chang-Panesso, M., Kadyrov, F. F., Lalli, M., Wu, H., Ikeda, S., Kefaloyianni, E., Abdelmageed, M. M., Herrlich, A., Kobayashi, A., & Humphreys, B. D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125519 · Cited by 158
Li, Y., Gan, Y., Liu, J., Li, J., Zhou, Z., Tian, R., Sun, R., Liu, J., Xiao, Q., Li, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00902-6 · Cited by 153
Martin-Mateos, R., De Assuncao, T. M., Arab, J. P., Jalan-Sakrikar, N., Yaqoob, U., Greuter, T., Verma, V. K., Mathison, A. J., Cao, S., Lomberk, G., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.005 · Cited by 73
Metadata
- Authors
- Wen, Y., Cai, J., Hou, Y., Huang, Z., & Wang, Z.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-03-22
- Volume
- 8
- Issue
- 23
- Pages
- 37974-37990
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2603097935
- Cited by
- 90
- References
- 8
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.